Revlimid (Lenalidomide) for the Treatment of Mantle Cell Lymphoma (MCL)
Revlimid (lenalidomide) oral capsules are indicated for the treatment of Mantle Cell Lymphoma (MCL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 10, 2013 Category: Pharmaceuticals Source Type: news
Lenalidomide Trial KO'd: A Blow to CLL Patients?Lenalidomide Trial KO'd: A Blow to CLL Patients?
Dr. Bruce Cheson discusses the clinical ramifications of the decision to halt the ORIGIN trial, which compared lenalidomide vs chlorambucil in previously untreated elderly patients with CLL. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 12, 2013 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
Pomalidomide Celgene® - (pomalidomide) licensed for use in the UK for the treatment of adults with relapsed/refractory multiple myeloma
Celgene has confirmed that Pomalidomide Celgene® - (pomalidomide), a new oral blood cancer therapy, has been granted Marketing Authorisation by the European Medicines Agency and is now available in the UK and Ireland. Pomalidomide is for use in combination with dexamethasone for the treatment of adults with relapsed and refractory multiple myeloma (rrMM) who have received at least two prior therapies including both lenalidomide and bortezomib, and have demonstrated disease progression while on their last therapy... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 12, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
Early Myeloma Treatment Slows Progression (CME/CE)
(MedPage Today) -- Patients treated with standard care for smoldering myeloma -- observation until symptoms develop -- had worse outcomes than early lenalidomide plus dexamethasone treatment, researchers found. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 1, 2013 Category: Hematology Source Type: news
